Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer

Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination defici...

Full description

Saved in:

Bibliographic Details
Main Authors:	Trudy J. Philips, Britt K. Erickson, Stefani N. Thomas
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	ovarian cancer PARP inhibitor proteogenomics immunotherapy biomarkers antibody drug conjugate (ADC)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1503107/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer
by: Jesenia M. Perez, et al.
Published: (2025-01-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis
by: Xiaolian Peng, et al.
Published: (2025-01-01)

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
by: Yulin Wang, et al.
Published: (2025-01-01)

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II
by: Zhi-Bin Wang, et al.
Published: (2025-02-01)

Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer
by: Sangsang Tang, et al.
Published: (2025-02-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
by: Yufei Wang, et al.
Published: (2025-02-01)

Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
by: Maurizio Capuozzo, et al.
Published: (2024-05-01)

Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer
by: Wei Tan, et al.
Published: (2025-01-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2025-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis
by: Shunlian Fu, et al.
Published: (2025-01-01)

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
by: Bita Jafary, et al.
Published: (2025-01-01)

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
by: Qi Xu, et al.
Published: (2024-10-01)

Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET
by: Andreas Evers, et al.
Published: (2024-12-01)

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
by: Romain Pacaud, et al.
Published: (2025-01-01)

Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy
by: David J. Benjamin, et al.
Published: (2025-01-01)

Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice
by: Yuanyuan Wang, et al.
Published: (2025-02-01)

Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer
by: Esen Yonca Bassoy, et al.
Published: (2025-12-01)

Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer
by: Shuo-Fu Chen, et al.
Published: (2024-09-01)

Electrostatic properties of human germlines and biodistribution of small biologics
by: Leticia Maria De Souza Cordeiro, et al.
Published: (2024-12-01)

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis
by: Nobuaki Matsubara, et al.
Published: (2025-01-01)

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
by: Ugochi Ebinama, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer
by: Elizabeth T. Evans, et al.
Published: (2024-09-01)

Assessment of Thyroid Auto-antibodies in Euthyroid Infertile Women with Polycystic Ovarian Syndrome - A Cross-sectional Analytical Study
by: K. H. Anusha, et al.
Published: (2024-12-01)

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis
by: Shiya Ji, et al.
Published: (2025-01-01)

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
by: Matteo Perra, et al.
Published: (2025-01-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01)

SAR-Assisted Energy-Efficient Hybrid ADCs
by: Kent Edrian Lozada, et al.
Published: (2024-01-01)

Tumor biomarkers contribute to the diagnosis and clinical management of the O-RADS MRI risk stratification system for epithelial ovarian tumors
by: Shengjie Xu, et al.
Published: (2025-01-01)